Product Overview

Menotropin HMG 150iu Injection, supplied by German Remedies Private Ltd, is a standardized preparation of human menopausal gonadotropin (HMG) indicated for the management of female infertility associated with anovulation or oligo‑ovulation, as well as for the treatment of male hypogonadism and related infertility. Each vial contains 150 international units of purified HMG, combined with a sterile diluent of 1 mL of 0.9 % sodium chloride solution for reconstitution. The medication is presented as a single injection per vial, enabling precise dosing regimens tailored to individual patient protocols. This product is classified within the therapeutic category of female infertility, reflecting its primary clinical application in assisted reproductive technologies.

What is Menotropin HMG 150iu Injection?

Menotropin HMG is a heterogeneous mixture of gonadotropins extracted from the urine of post‑menopausal women. The preparation enriches the population of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity, mimicking the natural endocrine signals that regulate ovarian follicle development and testicular Leydig cell function. In clinical practice, the drug is administered subcutaneously or intramuscularly after reconstitution, providing a reliable source of gonadotropic stimulation. The generic version marketed under the label Menotropin HMG 150iu Injection contains the same active moiety as the reference biological products, offering a cost‑effective alternative without compromising therapeutic equivalence.

Uses and Benefits

The therapeutic utility of Menotropin HMG spans several reproductive endocrinology scenarios. In women, it is employed to induce ovulation in cycles of uncontrolled or unexplained infertility, and to augment follicular recruitment in controlled ovarian hyperstimulation protocols used for in‑vitro fertilization (IVF) and intrauterine insemination (IUI). In men, the same preparation can stimulate Leydig cell production of testosterone, addressing clinical manifestations of hypogonadism such as reduced libido, fatigue, and infertility. Clinical studies cited by authoritative sources such as the NIH have demonstrated comparable live‑birth rates when HMG is used in combination with recombinant gonadotropins, supporting its role as a benchmark therapy in reproductive medicine.

How It Works

Following reconstitution, the HMG preparation binds to specific receptors on ovarian granulosa cells and testicular Leydig cells, activating intracellular signaling pathways that promote steroidogenesis and follicular maturation. In the ovary, increased FSH activity leads to the development of multiple primordial follicles, while LH activity triggers the final maturation and eventual ovulation of the dominant follicle. In the testes, HMG stimulates the production of androgens that support spermatogenesis and improve sperm parameters. The heterogeneous composition of the drug provides a balanced FSH‑to‑LH ratio that approximates physiological gonadotropic secretions, thereby optimizing the endogenous reproductive cascade.

Dosage Guidelines

Dosage of Menotropin HMG must be individualized based on patient age, ovarian reserve, body mass index, and prior response to stimulation. Typical clinical protocols initiate therapy with a single daily injection of 75 to 150 international units, administered subcutaneously for a duration of 6 to 12 days, depending on follicular growth observed through ultrasound monitoring. Adjustments are made to achieve a target endometrial thickness and optimal follicular size before proceeding to oocyte retrieval or timed intercourse. For male patients, the recommended regimen generally consists of 150 international units administered intramuscularly every other day for a minimum of three months, with periodic assessment of serum testosterone levels. Clinicians are advised to consult the prescribing information and local regulatory guidance for detailed dosing algorithms, as the optimal schedule may vary according to institutional protocols and patient‑specific factors.

Side Effects

Like all biologics, Menotropin HMG can be associated with adverse events, most of which are mild to moderate and self‑limiting. Commonly reported side effects include injection site reactions such as redness, swelling, or bruising, as well as transient abdominal discomfort. Hormonal stimulation may occasionally lead to ovarian hyperstimulation syndrome (OHSS), manifested by abdominal distension, nausea, and rapid weight gain; clinicians should monitor patients closely for these signs. In rare instances, hypersensitivity reactions or thromboembolic events have been documented, warranting immediate medical evaluation. Patients are encouraged to report any unexpected symptoms to their healthcare provider and to review the product’s safety profile on authoritative sites such as MedlinePlus.

Warnings and Precautions

Menotropin HMG is contraindicated in individuals with known hypersensitivity to gonadotropins, active ovarian cysts, or certain reproductive cancers. Caution is advised in patients with a history of thromboembolic disorders, severe pelvic infections, or uncontrolled thyroid disease. The medication should not be used concomitantly with other gonadotropin agents without professional oversight, as combined stimulation may increase the risk of multiple gestation. Pregnant women must avoid exposure, and breastfeeding is discouraged due to potential transfer of hormonal components. Regular laboratory monitoring, including serum estradiol and testosterone assessments, is recommended to ensure therapeutic efficacy while minimizing safety concerns.

Frequently Asked Questions

1. What condition does Menotropin HMG 150iu Injection treat? It is indicated for female infertility due to anovulation or oligo‑ovulation, and for male hypogonadism and related infertility, as described by the FDA’s drug labeling.
2. How should the medication be stored? Unopened vials should be kept refrigerated at 2 °C to 8 °C; once reconstituted, the solution can be stored at room temperature for up to 24 hours, after which it must be discarded.
3. Can Menotropin HMG be used in combination with other fertility drugs? Yes, it is frequently combined with recombinant LH, GnRH analogues, or aromatase inhibitors under medical supervision to tailor stimulation protocols.
4. Is the product available in different pack sizes? Pack configurations include 3 vials with 3 sodium chloride ampoules, 6 vials with 6 ampoules, and 9 vials with 9 ampoules, each containing a single 150iu dose per vial.
5. Where can I find more detailed prescribing information? Comprehensive guidance is available on the NIH’s reproductive health resources and the FDA’s drug database, providing evidence‑based dosing, contraindications, and adverse‑event reporting.

Related Products

• Azelastine Nasal Spray (Generic)
• Arzep Nasal Spray (Azelastine)
• Vigora 100 mg (Sildenafil Citrate)
• Vigora Tablet (Sildenafil Citrate)
• Vigora Lido Spray (Lidocaine)
• Vigore Gold 100 mg (Sildenafil Citrate)
• Vigore Force 80 mg (Sildenafil/Dapoxetine)
• Tadora 20 mg (Tadalafil)
• Vigora 50 mg (Sildenafil Citrate)
• Tadora Force 80 mg(Tadalafil/Dapoxetine)
• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)